IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma
Craig C Carson, Stergios J Moschos, Sharon N Edmiston, David B Darr, Nana Nikolaishvili-Feinberg, Pamela A Groben, Xin Zhou, Pei Fen Kuan, Shaily Pandey, Keefe T Chan, Jamie L Jordan, Honglin Hao, Jill S Frank, Dennis A Hopkinson, David C Gibbs, Virginia D Alldredge, Eloise Parrish, Sara C Hanna, Paula Berkowitz, David S Rubenstein Show all
CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2015
Awarded by National Cancer Institute (NCI)
Awarded by National Institute of Environmental Health Sciences (NIEHS)
Awarded by National Center for Advancing Translational Sciences
This work was supported by National Cancer Institute (NCI) grants R33CA10704339 (to N.E. Thomas and K. Conway), R21CA134368 (to N.E. Thomas and K. Conway), R01CA112243 (to N.E. Thomas), and P30CA016086; National Institute of Environmental Health Sciences (NIEHS) grant P30ES010126; University Cancer Research Fund (UCRF) at University of North Carolina (UNC) Chapel Hill's Lineberger Comprehensive Cancer Center (LCCC; to N.E. Thomas); Harry J. Lloyd Charitable Trust (to N.E. Thomas and S.J. Moschos); UNC LCCC Developmental Grant; The V Foundation (to N.E. Thomas and D.W. Ollila); Doris Duke Charitable Foundation Clinical Research Fellowship (to S. Pandey and V.D. Alldredge); National Center for Advancing Translational Sciences award ULTR000083 (to N.E. Thomas); and The Irene and Robert Alan Briggaman Distinguished Professorship (to N.E. Thomas). UCRF supported, in part, work in the Mouse Phase 1 Unit (MP1U) and the UNC Translational Pathology Laboratory (TPL).